2004年07月29日
虚血再灌流障害を防止する
この論文で紹介されているRepertaxinという低分子薬剤が虚血再灌流傷害を防止する？！
Bertini et al., 10.1073/pnas.0402090101
Abstractは以下の通りです..
Abstract
The chemokine CXC ligand 8 (CXCL8)/IL-8 and related agonists recruit and activate polymorphonuclear cells by binding the CXC chemokine receptor 1 (CXCR1) and CXCR2. Here we characterize the unique mode of action of a small-molecule inhibitor (Repertaxin) of CXCR1 and CXCR2. Structural and biochemical data are consistent with a noncompetitive allosteric mode of interaction between CXCR1 and Repertaxin, which, by locking CXCR1 in an inactive conformation, prevents signaling. Repertaxin is an effective inhibitor of polymorphonuclear cell recruitment in vivo and protects organs against reperfusion injury. Targeting the Repertaxin interaction site of CXCR1 represents a general strategy to modulate the activity of chemoattractant receptors
投稿者 hif1 : 2004年07月29日 17:30
トラックバック
このエントリーのトラックバックURL:
http://dp54020279.lolipop.jp/cgi/mt/mt-tb.cgi/10